NanoViricides (NNVC) Stock Price, News & Analysis

Company Overview

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Key Stats

• Today's Range: $1.27 to $1.37
• 50-Day Range: $1.03 to $1.42
• 52-Week Range: $0.94 to $3.59
• Volume: 85,979 shs
• Average Volume: 264,542 shs
• Market Capitalization: $20.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NNVC Stock Analysis - Frequently Asked Questions

How have NNVC shares performed this year?

NanoViricides' stock was trading at $1.43 at the start of the year. Since then, NNVC shares have decreased by 9.1% and is now trading at $1.30.
View the best growth stocks for 2025 here.

How were NanoViricides' earnings last quarter?

NanoViricides, Inc. (NYSE:NNVC) announced its quarterly earnings data on Friday, September, 27th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01.

When did NanoViricides' stock split?

Shares of NanoViricides reverse split on the morning of Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are NanoViricides' major shareholders?

NanoViricides' top institutional shareholders include Compagnie Lombard Odier SCmA (1.28%) and Wealth Enhancement Advisory Services LLC (0.14%).
View institutional ownership trends.

How do I buy shares of NanoViricides?

Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), NVIDIA (NVDA), Micron Technology (MU), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 9/27/2024
• Today: 5/02/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NNVC
• CIK: 1379006
• Web: www.nanoviricides.com
• Phone: (203) 937-6137
• Fax: 203-859-5095
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,290,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.90%
• Return on Assets: -78.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 2.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 1.97

Miscellaneous

• Outstanding Shares: 15,641,000
• Free Float: 14,922,000
• Market Cap: $20.33 million
• Optionable: Optionable
• Beta: 0.93